Document:

Exhibit 10.2

 

FOUNDERS AND SHAREHOLDERS AGREEMENT

 

THIS AGREEMENT is made as of the   day of January, 2001

 

AMONG:

 

(1)                                 Clal Biotechnology Industries Ltd.

an Israeli Company. No. 51-189883-5

of Atidim Tower, Atidim Industrial Park

Israel, (“CBI”); and

 

(2)                                 L.R. R&D Ltd.

an Israeli Company, No. 51-181950-0

of 13 Harduf Street, Omer,

Israel, (“LR”); and

 

(3)                                 Prof. Lior Rosenberg

Israeli ID No. 0809587-9

of 13 Harduf Street, Omer,

Israel, (“Rosenberg”); and

 

(4)                                 Mediwound Ltd.

an Israeli Company, No.51-289494-0

of Atidim Tower, Atidim Industrial Park

Israel, (“Company” or “Mediwound”)

 

WHEREAS

 

(1)                                 On or about January, 2000, CBI and LR jointly established the company for the purpose of the research and development, manufacturing, marketing and sale of wound healing and burn treating products and modalities, including, without limitation, a product derived from Pineapple stems and used for wound healing (“Debridase”) and other activities ancillary or incidental thereto (collectively, the “Business”);

 

(2)                                 LR is one of the Initiators of this project and is the sole rightful owner of clinical results and intellectual property related to Debridase included in the patents and patent applications, details of which are set forth in Exhibit A attached hereto (Appendix A to the MOU executed between the parties, dated January 20th, 2000), and all information, know-how and materials relating thereto (the “IP”);

 

(3)                                 The parties wish to work together and co-operate with each other to enable the grant of the exclusive license of the IP to the Company and to assist the company in the future development, clinical use and commercial exploitation of the IP and any products deriving therefore including without limitation, the Debridase, and other activities ancillary or incidental to the Business;

 

 

(4)                                 Prior to or shortly following the signing of this Agreement by the parties, the Company has entered or will enter into: (a) an Agreement with Mark Klein/Bioproducts Inc. for the transfer of its intellectual property relating to Debridase to the sole ownership of the Company, a copy of which is attached hereto as Exhibit B; and (b) Agreement with Challenge Bioproducts Corporation Ltd./Dr. CK Lin, for the exclusive supply of Debridase-related raw material to the Company, and for Technology Transfer relating to said raw material, copies of which is attached hereto as Exhibits C1 and C2 (collectively, the “Related IP and Supply Agreements”);

 

(5)                                 The parties have agreed upon certain matters relating to the manner in which the Company is to be held and conducted, including the ownership, administration and management thereof, and upon certain other matters and are desirous of recording such agreement in writing.

 

NOW THEREFORE, it is hereby agreed among the parties hereto as follows:

 

1.                                      Defined Terms

 

1.1                               The following words and expressions shall bear meanings set opposite them:

 

	
“Affiliate”
    	
 
    	
a Person directly or indirectly   controlling, controlled by or under common control with any other Person. As   used in this definition “control” of an entity means the possession, directly   or indirectly, of the unilateral power to cause the direction of the   management and polices of such entity, whether through the ownership of   voting securities or otherwise.
    
	
 
    	
 
    	
 
    
	
“Business”
    	
 
    	
the business, as defined in the   Preamble.
    
	
 
    	
 
    	
 
    
	
“Board”
    	
 
    	
the Board of Directors of the Company.
    
	
 
    	
 
    	
 
    
	
“Commencement Date”
    	
 
    	
the date of the commencement of the term   of this Agreement, as provided in Section 13.
    
	
 
    	
 
    	
 
    
	
“Company”
    	
 
    	
Mediwound Ltd., a company incorporated   in the State of Israel.
    
	
 
    	
 
    	
 
    
	
“Dollar” or “$”
    	
 
    	
a dollar of the United States of   America.
    
	
 
    	
 
    	
 
    
	
“Person”
    	
 
    	
a natural person or corporation trust,   association partnership, limited liability company, joint venture or other   entity (including a governmental agency or instrumentality).
    
	
 
    	
 
    	
 
    
	
“Shareholders”
    	
 
    	
CBI and LR.
    

 

1.2                               In this Agreement, unless there is something in the subject or context Inconsistent therewith:

 

2

 

1.2.1                     words importing the singular shall (where appropriate) mean and include the plural and vice versa;

 

1.2.2                     words importing any one gender shall (where appropriate) mean and include the other gender and vice versa;

 

1.2.3                     words importing natural persons shall (where appropriate) mean and include corporations and other entities and vice versa; and

 

1.2.4                     the headings are for convenience of reference only and shall not be construed as affecting the meaning or interpretation of this Agreement.

 

2.                                      Constituent Document — the Company

 

It is hereby acknowledged and agreed that the Memorandum and Articles of Association of the Company are or will be in the Form attached hereto as Exhibit D, as may be amended from time to time in accordance with the provisions of this agreement and the Articles of Association of the Company.

 

3.                                      Shareholder — Company

 

3.1                               Subject to the provisions of this Agreement, the issued and outstanding share capital of the Company, which shall initially comprise of 10,000 (ten thousand) Ordinary Shares of NIS 1.0 per share, shall be held, in the following proportions:

 

CBI — eighty per cent (80%), 8000 shares;

LR — twenty per cent (20%), 2000 shares (“LR’s Initial Percentage Shareholding”).

 

3.2                               In consideration of LR granting the license to the Company pursuant to Section 7.1, it is hereby agreed that in the event of the issuance of any shares by the Company to CBI and/or any third parties in exchange for the investment by such parties in the Company, LR shall be entitled to maintain LR’s Initial Percentage Shareholding through the issuance of such sufficient additional number of fully paid issued ordinary shares by the Company to LR, for no additional payment, as shall be necessary to restore LR’s Initial Percentage Shareholding, provided that the anti-dilution protection provided in this Section 3.2 shall cease to apply after a total of [Twelve Million United States Dollars (US$12,000,000)] shall have been invested in the Company by CBI and/or any third parties.

 

3

 

4.                                      Board of Directors — Company

 

4.1                               The Shareholders undertake towards each other to vote and/or procure the voting at all meetings of the Shareholders and Board to elect the directors of the Company in accordance with the provisions of this Section 4.

 

4.2                               Each of the Shareholders shall be entitled to designate such number of persons to the Board as shall be pro rata to its respective shareholding in the Company.

 

4.3                               Directors of the Company designated by any of the Shareholders shall be removed or replaced upon the written instruction of the party which nominated such director.

 

4.4                               The Board shall consist of at least 3 (three) persons, and shall initially consist of the following persons:

 

Dr. Avri Havron, Adv. Ophir Shahaf, as designated by CBI; and

 

Rosenberg, designated by LR (“LR’s Director”).

 

4.5                               The Board shall convene at least once every quarter, or as required.

 

5.                                      Active Chairman and Chief Medical Director

 

5.1                               The Active Chairman of the Company shall be nominated and appointed by the Board.

 

5.2                               Rosenberg shall be appointed as Chief Medical Director of the Company and, in connection therewith, Rosenberg and the Company shall sign the Employment Agreement on the date hereof, in the form attached hereto as Exhibit E.

 

6.                                      Decision-Making — Fundamental Matters and Procedures

 

6.1                               It is hereby expressly agreed that so long as LR holds at least ten percent (10%) of the issued shares of the Company on a fully diluted basis, and prior to the Company’s IPO (i) actions of the Company or any of its subsidiaries (as applicable) involving any of the following matters shall require the affirmative vote of LR, if such action is presented to the shareholders of the Company and (ii) the Company shall refrain from taking and, as applicable, shall not allow the company’s subsidiaries to take, the following actions should LR’s Directorsvote against the taking of said action, if such action may be taken by the Board of Directors:

 

6.1.1                     Appointment or removal of the Active Chairman of the Company.

 

4

 

6.1.2                     an acquisition of another company or business entity by the Company, or by another person or entity of the Company, whether through merger, purchase of shares, purchase of assets or otherwise.

 

6.1.3                     entering into any agreement or arrangement between the Company and (a) one of the Shareholders, or (b) an Affiliate of any of the Shareholders.

 

6.1.4                     offering, issuance or sale of additional securities or any instruments convertible into securities, or options to acquire shares in the Company, provided that this Section 6.1.4 shall not apply to any such issuance effected in accordance with the provisions of Section 8.

 

6.1.5                     purchase or redemption of the securities of the Company, or the pledge thereof.

 

6.1.6                     stock split, consolidation, merger, recapitalization or capital contribution.

 

6.1.7                     amendment to the Articles of Association of the Company.

 

6.1.8                     approval or making of any voluntary bankruptcy or reorganization filing, or approval of the dissolution, liquidation or other termination of business or operations of the Company.

 

6.1.9                     entering into any new fields of activity other than the Business.

 

6.1.10              The sub-licensing of any part of the IP by the Company.

 

6.1.11              Changing the duties and responsibilities of the Company’s Chief Medical Director, other than termination.

 

6.2                               Subject to Section 6.1, all decisions at meetings of the Board and Shareholders of the Company shall be made on a simple majority basis, provided that a member of the Board may vote by proxy.  The Board and Shareholders may also act by unanimous written consent in lieu of a meeting.

 

6.3                               The Company shall adopt, a set of procedures concerning such of the following matters as the Company deems appropriate, and concerning any other matters that the Company deems appropriate:

 

6.3.1                     calling of meetings, including notice requirements and procedures for waiver of notice;

 

6.3.2                     place of meetings;

 

6.3.3                     participating in meetings by telephone;

 

6.3.4                     procedures for developing information required by the Board; and

 

6.3.5                     keeping of minutes and approval thereof.

 

5

 

7.                                      License of Intellectual Property

 

7.1                               Exclusive License.  In consideration of LR receiving the shares in the Company, at par value, as provided in Section 3.1 and also being provided with the benefit of the anti-dilution protection expressly provided in Section 3.2 and in further consideration of the due and proper payment of the amounts provided in Section 7.6, LR hereby grants the Company, and the Company hereby accepts, an exclusive non-revocable royalty-free worldwide license (the “Exclusive License”), to use and exploit the IP and any part thereof, including without limitation to sublicense (subject to Section 7.3 below), copy, reproduce and/or modify the IP or any part thereof, and to research, develop, produce license (subject to Section 7.3 below), market, distribute and sell products based on, or involving the use of, the IP, for any legal use whatsoever (the “Products”).

 

7.2                               Term.  The Exclusive License shall remain in force in perpetuity, unless terminated by mutual written agreement of the parties hereto, or in the event that the Company shall not have a yearly financial cash flow or transactions of any kind of at least Three Hundred Thousand United States Dollars ($300,000).

 

7.3                               Sublicense.  The Company may upon the execution hereof grant sublicenses to use and exploit the IP and any part thereof, including without limitation to sublicense, copy, reproduce and/or modify the IP or any part thereof, and to research, develop, produce, market, distribute and sell any of the Products (the “Sublicenses”), provided that such sublicenses shall be pursuant to an agreement which shall provide as follows:

 

(i)                                     The Sublicense may be used solely for any legal use; and

 

(ii)                                  The Sublicense shall terminate promptly upon the termination of the Exclusive License.

 

7.4                               Representations.  LR and Rosenberg hereby jointly and severally represent and warrant that:

 

7.4.1                     The IP is in the exclusive, full and legal ownership of LR free and clear of all liens, claims and restrictions and, to the best of its knowledge, without infringing upon or violating any right, lien, or claim of others.  LR is not obligated or under any liability whatsoever to make any payments by way of royalties, fees or otherwise to any owner or licensee of, or other claimant to, any patent, trademark, service mark, trade name, copyright or other intangible asset, with respect to the use of the IP.  LR has taken of all the IP, which measures are reasonable and customary in the industry in which CBI operates.

 

7.4.2                     To LR’s best knowledge, the rights in the IP are not currently infringed or violated by any person or entity.

 

6

 

7.5                               Title.  Any and all new intellectual property of any kind, whether patentable or not, including without limitation, documentation, drawings, reports, surveys, correspondence, formula data and specification which are not existing and dated prior to the date hereof, which is currently or will be developed in the future, by the Company, Rosenberg, LR and their respective employees, officers or consultants relating to chemical or Enzymatic Debridement shall be the property solely of the Company.

 

7.5.1                     LR hereby grants the Company a right of first offer to commercialize any and all other intellectual property, not included in this agreement, that it has developed or will develop, in all fields.  The Company shall inform LR of its decision regarding commercialization of said intellectual property within 60 days of the proposal.

 

7.6                               Payments by Company.  In consideration of LR hereby granting the Exclusive License to the Company, it hereby agrees to make the following payments to LR:

 

7.6.1                     One Hundred and Fifty Thousand United States Dollars (US$150,000) — immediately upon the execution of this Agreement by LR and Rosenberg and the execution of the Related IP and Supply Agreements by all the parties thereto;

 

7.6.2                     Fifty Thousand United States Dollars (US$50,000) — on the first anniversary of the later of the execution of this Agreement by the parties and the date of execution of the Related IP and Supply Agreements by all the parties thereto (the later of such dates being referred to as the “Relevant Date”);

 

7.6.3                     Fifty Thousand United States Dollars (US$50,000) — eighteen (18) months after the Relevant Date;

 

7.6.4                     Fifty Thousand United States Dollars (US$50,000) — upon first filing for registration of the Company’s Debridase-based product with the FDA (US) or with the equivalent European authorities, if filed in a Western European country; and

 

7.6.5                     One Thousand United States Dollars (US$100,000) — upon first approval for registration of the Company’s Debridase-based product by the FDA (US) or by the equivalent European or Japanese authorities, if approved in a Western European country or Japan.

 

7.6.6                     The Company shall reimburse LR for expenses related to the registration of IP that shall be assigned to the Company, that have occurred since January 2000, and until the signing of this agreement, against proper documentation.

 

7.7                               LR and Rosenberg shall, at the request of the Company, sign, execute, deliver and file all such documents, agreements, consents, forms, and statements as may be requested at any time hereafter by the Company for the purposes of perfecting the Exclusive License

 

7

 

hereby granted and securing the rights of the Company therein and to the IP.  LR shall sign and deliver to the Company a separate form of License Agreement, to be prepared by the Company and which substantially reflects the terms of the Exclusive License as contained in this Section 7.

 

8.                                      Pre-emptive Rights

 

8.1                               If the Company proposes to issue or sell any New Securities (as defined in Section 8.2.1) prior to the consummation of an IPO, the Company shall before such issuance offer to all holders of shares in the Company (“Shares”) the right to purchase a pro-rata share of the New Securities.  A Shareholder’s pro-rata share, for purposes of this section, is the ratio of the number of shares owned by such Shareholder immediately prior to the issuance of New Securities in relation to the total number of Shares outstanding immediately prior to the issuance of New Securities.  Each holder of Shares shall have a right of over-allotment such that if any shareholder fails to exercise its right hereunder to purchase its pro-rata share of New Securities, each other Shareholder exercising its preemptive rights hereunder may purchase the non-purchasing shareholder’s portion pro-rata according to the respective total number of Shares owned by such other Shareholders exercising this right of over allotment within seven (7) days from the date such non-purchasing shareholder fails to exercise its rights hereunder to purchase its pro-rata share of New Securities.  This preemptive right shall be subject to the following provisions:

 

8.1.1                     “New Securities” shall mean any equity interest in the Company, whether now authorized or not, and rights, options or warrants to purchase such equity interest, and securities of any type whatsoever that are convertible into equity interests; provided that the term “New Securities” does not include:  (a) securities issuable upon conversion of convertible securities or upon the exercise of warrants which were New Securities when issued; (b) the Company’s Shares issued in connection with any stock split, stock dividend, recapitalization, reclassification or similar event by the Company; or (c) shares to be issued to employees, directors or consultants of the Company in accordance with the resolutions of the Board as part of a bona fide employee share option plan approved by the Board.

 

8.1.2                     In the event the Company proposes to undertake an issuance of New Securities, it shall give each Shareholder written notice of its intention, describing the type of New Securities, their price and the general terms upon which the Company proposes to issue the same.  Subject to Section 8.1, each Shareholder shall have seven (7) days after any such notice is mailed or delivered to agree to purchase such Shareholder’s pro rata share of such New Securities of the price and upon the terms specified in the notice by giving written notice to the Company stating therein the quantity of New Securities to be purchased and transferring the full consideration for those New Securities to the Company’s bank account.

 

8

 

8.2                               Subject to Section 8.1, in the event the Shareholders fail to exercise fully the preemptive right within the said fourteen (14) day period and after the expiration of the ten-day period for the exercise of the over-allotment or allotment provisions of Section 8.1, the Company shall have one hundred sixty (160) days thereafter to sell or enter into an agreement to sell the New Securities respecting which the Shareholders’ preemptive right set forth in Section 8.1 is not exercised, at a price and upon terms no more favorable to the purchasers thereof than specified in the Company’s notice to the Shareholders pursuant to Section 8.1.  In the event the Company has not sold or entered into an agreement to sell the New Securities in accordance with the foregoing within one hundred sixty (160) days, the Company shall not thereafter issue or sell any New Securities without first again offering such securities to the Shareholders in the manner provided in Section 8.3.

 

8.3                               Notwithstanding anything to the contrary herein contained, the Company may issue New Securities to CBI and/or any third party for a total investment in the Company of up to [Twelve Million Unites States Dollars (US$12,000,000)] without complying with the foregoing provisions of this Section 8 or Section 6.1.4.

 

9.                                      Right of First Refusal

 

9.1                               The term “Permitted Transferee” means any of the following:

 

9.1.1                     the spouse (or widow or widower) of the transferor and the transferor’s children (including step and adopted children) (each of the Transferees in Section 9.1.1 are referred to as a “Privileged Relation”).

 

9.1.2                     a trust which does not permit any of the settled property or the income therefrom to be applied otherwise than for the benefit of the relevant transferor-shareholder and/or a Privileged Relation of that transferor-shareholder and no power of control over the voting powers conferred by any shares are subject to the consent of any person other than the trustees of such transferor-shareholder or his Privileged Relations.

 

9.1.3                     a company in which the transferor owns directly or indirectly more than 50% of the equity and voting capital or has the right or power to direct the policy and management of such company or a company that owns directly or indirectly more than 50% of the equity and voting capital or has the right or power to direct the policy and management of the transferor, provided that the transferor agrees to reacquire the transferred securities in the event the conditions set forth in this Section 9.1.3 cease to be satisfied.

 

9.1.4                     in the case of a transferor being a partnership, its general or limited partner or any affiliated partnership managed by the same or affiliated management company or of which the general partner of the transferor is a general partner, or to a trustee or beneficiary of a trust which holds all of the shares in the body corporate, provided that the transferor agrees to reacquire the transferred securities in the event the conditions set forth in this Section 9.1.4 cease to be satisfied.

 

9

 

9.2                               The term “Permitted Transfer” means a Transfer to a Permitted Transferee, subject to any terms and conditions contained in this Agreement and the Articles of Association of the Company; provided, that a Transfer of any share pursuant to this Section shall only be treated as a Permitted Transfer if it is a Transfer of the entire legal and beneficial interest in such share free from all liens, charges and other encumbrances and if the transferee agrees in writing to be bound by the terms and conditions of this Agreement and the Articles of Association of the Company.

 

9.3                               Except for Permitted Transfer in accordance with Section 9.2, in any case where a Shareholder (in this Section 9.3, the “Selling Shareholder”) desires to sell or Transfer any or all of his or its shares in the Company (the “Offered Shares”), it shall first give written notice thereof (“Notice of Sale”) to all of the holders of the Shares (the “Optionholders”).

 

9.3.1                     The Notice of Sale shall state the number of Offered Shares, that the Offered Shares will, upon the sale, be free of all liens, charges and encumbrances, that a bona fide offer has been received from a third party, and the price, terms of payment and conditions for this purchase of the Offered Shares.  Upon receipt of the Notice of Sale, the Optionholders shall have the right to the exercise the option (the “Option”) contained in Section 9.3.2.

 

9.3.2                     For a period of 30 days after receipt of the Notice of Sale, the Optionholders may elect to purchase all (but not part) of the Offered Shares.  The Option shall be exercised by delivery of a notice to such effect to the Selling Shareholders within 30 days of receipt of the Notices of Sale.  If more than one of the Optionholders exercises the Option (the “Buying Shareholders”), they shall acquire the Offered Shares pro rata according to the shareholding ratio among such Buying Shareholders as of the date immediately prior to the sale of such Offered Shares pursuant to this Section.  The purchase of the Offered Shares shall be on the same terms and conditions as stated in the Notice of Sale.

 

9.3.3                     If all of the Offered Shares are not sold to the Optionholders, then the Selling Shareholder shall be free, within 60 days of the date of expiration of the Option, to sell such shares to a prospective buyer, at the price and on the terms contained in the Notice of Sale.  If there is no sale within such 60 day period, the Selling Shareholder shall not sell or Transfer the Offered Shares, or any other shares acquired before or after the date hereof, without again complying with the provisions of this Section 9.3.

 

9.4                               In the event that there is a situation in which fractional shares will need to be transferred, the number of shares will be rounded up so that only full shares will be transferred.

 

9.5                               The provisions of Section 8, 9 and 10 shall be of no further force and effect upon the consummation of an IPO by the Company.

 

10

 

10.                               Bring Along Rights

 

10.1                        Prior to IPO, in the event that shareholders in the Company holding more than 66% of the Company’s issued shares (on a fully diluted, as if converted basis) (the “Proposing Shareholders”) accept an offer (“Section 13.1 Offer”) to sell all of their shares of the Company to a third party, and such sale is conditioned upon the sale of all remaining shares of the Company to such third party, all other Shareholders (“Non-Proposing Shareholders”) shall be required to sell their shared in such transaction, on the same terms and conditions.  Said requirement shall enter into effect only in the event that the mentioned sale is performed at a Company pre-money valuation of at least $ 20 M (Twenty million United States Dollars).

 

10.2                        In the event that the threshold percentages of Section 10.1 are met, any Transfer or hypothecation of shares by the Non-Proposing Shareholders other than in connection with the proposed acquisition shall be absolutely prohibited, and at the closing of such Offer all the Shareholders of the Company shall sell all of their shares to the person or entity making such Offer on the same terms and conditions as contained in the Offer, provided, however, that the aggregate consideration provided pursuant to the closing of such Offer shall be allocated among the Company’s Shareholders in accordance with the Articles of Association of the Company.  In the event that a Shareholder fails to surrender its share certificate in connection with the consummation of a Section 10.1 Offer, such certificate shall be deemed cancelled and the Company shall be authorized to issue a new certificate in the name of the person making the Offer and the Board shall be authorized to establish an escrow account, for the benefit of the Shareholder, into which the consideration for such cancelled shares shall be deposited and to appoint a trustee to administer such account.

 

10.3                        In any event of said sale (CBI’s and LR’s shares of the Company to a third party), LR will have the opportunity to join the sale on same terms, pro-rata to the parties holdings of the Company shares at the time of the sale.

 

11.                               Non-Competition and Confidential Information

 

Each of the parties, except for the Company, covenants and undertakes that for as long as it maintains any shares in the Company (and in the case of Rosenberg, it or LR), and for two (2) years thereafter (hereafter “the Restricted Period”), except as otherwise agreed in writing with the Company:

 

11.1                        neither it nor its Affiliates shall, either solely or jointly with or as manager agent or consultant of any other person (corporate or unincorporated) carry on or be engaged or concerned or interested, directly or indirectly, in Israel, the United States, the European

 

11

 

Community or Japan in the business of research and development, manufacturing, marketing and sale of bio-chemical debridement agents, including without limitation, a product derived from Pineapple stems and used for would healing, other than through the Company (“Restricted Activity”).

 

11.2                        it and its Affiliates will keep confidential and not disclose or make use of any financial information of the Company or other information relating to the business and affairs of the Company and its property and assets, including but not limited to any such information about current or future affairs or plans or clients or other persons with whom any of the parties hereto or the Company has had dealings or is or has been concerned in relation to the business and affairs of the Company and its property and assets.  For the avoidance of doubt, it is clarified that membership on the Board of Directors of any company does not constitute a breach of this section 11.2, provided that this section 11.2 is otherwise complied with.

 

This section does not apply to information:

 

a)                                     which is now or hereafter is published or becomes known publicly or otherwise becomes part of the public domain through no fault of the parties or Affiliates thereof; or

 

b)                                     which is received by the parties or Affiliates thereof from sources other than the Company, which sources were not known by the parties or Affiliates thereof to be under any obligation of secrecy to the Company; or

 

c)                                      which is specifically required to be disclosed in compliance with applicable laws or regulations or by order of a court or other regulatory body of competent jurisdiction.

 

12.                               Successors and Assigns

 

Except as otherwise specifically provided herein this Agreement shall be binding upon and enure for the benefit of the parties and their legal representatives, successors, heirs and permitted assigns.

 

13.                               Commencement and Term of Agreement

 

This Agreement shall take effect as and from the date of the signing hereof and shall continue in full force and effect to govern the relationship of the parties hereto until the liquidation or other termination of the business and operations of the Company.

 

12

 

14.                               Governing Law

 

This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Israel, without regard to principles of conflicts of law.

 

15.                               Notices

 

Any notice, declaration or other communication required or authorized to be given by any party under this agreement to any other party shall be in writing and shall be personally delivered or sent by facsimile transmission addressed to the other party at the address or facsimile number stated for such party in the preamble to this Agreement or such other address as shall be specified by the party in question by notice in accordance with the provisions of this Section 15.  Any notice shall operate and be deemed to have been served on the next following business day.

 

16.                               General

 

16.1                        All of the parties to this Agreement will do acts and things and sign and execute all documents and deeds and procure the passing of all corporate resolutions requisite for the purpose of implementing the terms of this Agreement.

 

16.2                        Except as provided herein, this Agreement contains the whole agreement between the parties relating to the subject matter hereof and supersedes all previous agreements or Memoranda of Understanding between such parties in respect of such.

 

16.3                        Nothing contained in this Agreement whether express or implied shall be read and construed so as to place all or any of the parties hereto in the relationship of a partnership.

 

16.4                        No failure or delay by either of the parties in exercising any claim, remedy, right, power or privilege under this Agreement shall operate as a waiver nor shall any single or partial exercise of any claim, remedy, right, power of privilege preclude any further exercise thereof or exercise of any other claim, right, power or privilege.

 

16.5                        This Agreement may be executed in two or more counterparts each of which shall be deemed an original but all of which constitute one and the same instrument.

 

16.6                        Save as expressly provided herein, this Agreement may be amended or terminated, and any of the terms hereof waived, only by a document in writing specifically referring to this Agreement and executed by the parties hereto or, in the case of a waiver, by the party waiving compliance.

 

13

 

16.7                        In case of any inconsistency between this Agreement and the Articles of Association of the Company, the provisions of this Agreement shall govern, and the parties shall promptly amend the Articles of Association, as applicable, of the Company to conform to this Agreement.

 

14

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and the year first above written.

 

 

	
Clal Biotechnology Industries Ltd.
    	
L.R. R&D Ltd.
    
	
 
    	
 
    
	
By:
    	
/s/D. Haselkorn   /s/G. Bieber
    	
 
    	
By: 
    	
/s/ Lior Rosenberg
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
D. Haselkorn /   G. Bieber
    	
 
    	
Name: 
    	
/s/ Lior Rosenberg
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
CEO / CFO
    	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Prof. Lior Rosenberg
    	
 
    	
Mediwound Ltd.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/ Lior   Rosenberg
    	
 
    	
By: 
    	
/s/MediWound Ltd.
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    

 

15

 

Exhibit A

 

The IP

 

The summary of the IP to be provided by Licensor to Licensee

 

Appendix A (copy of the original MOU with the addition of the Ultra Sound Enhanced Debriding patent application number that at the time of the MOU did not exist as yet)

 

1.                                      All the clinical data and material, patient’s files, photographic material, literature etc. concerning the Debridase project, wounds and burn handling generated and gathered by the Licensor during the last 16 years in clinical and in vivo settings.  International endorsement of the product and its application.  Rights for the new Minimal Invasive modality of wounds and burn treatment announced internationally at the ISBI meeting, November 1998 Jerusalem.

 

1.1.                            Completion (with Licensee support) of copying all required hospital patient’s files.

 

1.2.                            Support in compilation, analysis, documentation, edition and presentation of all retro and prospective clinical and other data in Israel and abroad, owned by the Licensor or by others, concerning Debridase.

 

1.3.                            Rights to Licensee of all the future publications based on Licensor existing (published and unpublished) clinical material.

 

2.                                      Rights relating to enzymatic debridement in several patents based on the two patent applications: PCT 4131/WO/96 and PCT 4132/WO/96 and the patent application number 10164 (2000) (Luzzatto&Luzzatto).

 

3.                                      Definition and development (with Licensee support) of the First Generation of Debridase clinical formulation(s) based on the above mentioned patents.

 

3.1.                            Support and supervision in establishing function efficacy evaluation and quality control test system that includes bioassay model (live piglets) and in-vitro model starting with fresh human skin (with licensee support).

 

3.2.                            Right of First Refusal to all future inventions.

 

4.                                      Definition and establishment (with Licensee support) of a multicenter clinical trial protocol.

 

4.1.                            Presentation and assessment of the existing data and the new multicenter protocol to the regulatory authorities.

 

4.2.                            Organization and coordination of leading burn centers for the multicenter trial.

 

4.3.                           Presenting, supporting and endorsing the project and the Debridase with the various, medical and military services.

 

16

 

Exhibit B

 

Assignment

 

·                  Whereas, all of the undersigned have entered into and executed two separate Memorandums of Understanding (“MOU”), detailing the terms and conditions of the in-licensing of IP and other rights and know-how related to Debridase; and

 

·                  Whereas, all undefined terms in this assignment document shall have the same definition and meanings as detailed in the MOU; and

 

·                  Whereas, CBI has established Mediwound Ltd., an Israeli private company (“Mediwound”) for the purpose of R&D, manufacturing, marketing and sales of the products derived from Pineapple stems and used for wound healing (“Debridase”); and

 

·                  Whereas, it is the Intention of the undersigned that Mediwound shall be the sole entity that shall be active in the R&D, manufacturing, marketing and sales of Debridase-related products;

 

Therefore, the undersigned agree:

 

All terms, rights and obligations detailed in the MOU and its Appendixes, relating to CBI - are hereby exclusively and irrevocably assigned to Med1wound, and all documents shall be construed as if Mediwound is a party to them instead of CBI.

 

 

	
 
    	
/s/Mark Klein
    	
 
    	
/s/Clal Biotechnology Industries Ltd.
    
	
 
    	
Mark Klein
    	
 
    	
Clal Biotechnology Industries Ltd.
    
	
 
    	
 
    	
 
    
	
 
    	
/s/CBC Ltd.
    	
 
    	
 
    	
/s/Lior Rosenberg
    
	
 
    	
CBC Ltd.
    	
 
    	
 
    	
LR R&D Ltd.
    
						

 

	
Date:
    	
28/1/2000
    	
 
    	
 
    

 

17

 

Exhibit C-1 and C-2

 

[Omitted — Supply Agreement]

 

18

 

Exhibit D

 

[Omitted - Memorandum and Articles of Association of the Company]

 

19

 

Exhibit E

 

[Omitted — Form of Employee Agreement]

 

20Exhibit 10.3

 

Unprotected Sub-Lease Agreement

 

Made and entered into on this 27 day of July, 2004

 

By and between:

 

Clal Life Sciences L.P. 
 Partnership No. 550208375
 Whose address for the purposes hereof is:
 42 Hayarkon Street
 Yavne 81227
 (hereinafter the “CLS”)

 

Of the First Part;

 

And:

 

MediWound Ltd. 
  Private Company no. 512894940
 Whose address for the purposes hereof is:
 42 Hayarkon Street
 Yavne 81227
 (hereinafter: “MediWound”)

 

Of the Second Part;

 

Whereas                                              Clal Biotechnology Industries Ltd. (“CBI”) and Taamiko Food Industries Ltd. (hereinafter referred to as the “Principal Lessor”) have executed a lease agreement (hereinafter the “Main Agreement”), regarding an area comprising in aggregate 2985 sq.m. as specified in the Main Agreement (hereinafter the “Main Premises”).  A copy of the Main Agreement is attached hereto as “Annex A”, and

 

Whereas                                              CBI has transferred its rights under the Main Agreement to the CLS and the Principal Lessor has approved the transfer of such rights.  A copy of such transfer and consent is attached hereto as Annex B; and

 

Whereas                                              CLS has received the permission of the Principle Lessor to sub-lease the Premises (as defined below), according to the above.  A copy of such permission is attached hereto as Annex C;

 

Whereas                                              MediWound has leased certain portion of the Main Premises from CLS, pursuant to an oral agreement between the parties, and MediWound has possession of that certain portion of the Main Premises; and

 

Whereas                                              MediWound declares and confirms that it has not paid CLS any “key money” or any other amount that may be deemed to be “key money’’; and

 

Whereas                                              the parties wish to establish a new formalized relationship between them, which shall reflect the fact that CLS wishes to sublease certain laboratories, offices and clean room space of an area of approximately 450 sq.m., on the ground & first floor of the Main Premises, as marked in the drawing attached hereto as “Annex D” and 13 parking spaces (hereinafter: the “Premises”) and allow MediWound to use certain general equipment

 

 

and MediWound wishes to rent the Premises and use the equipment, subject to the terms hereof;

 

Now, therefore, it is agreed, declared and stipulated between the parties as follows:

 

1.                                      Preamble

 

1.1                               The Preamble hereto and the Annexes hereof constitute an integral part hereof,

 

1.2                               The headings of the clauses and sub-clauses are for convenience only and shall have no interpretative effect.

 

2.                                      Parties’ Declarations

 

2.1                               CLS declares that it is entitled pursuant to any law and agreement, including the Main Agreement, to enter into this Sub-Lease Agreement with MediWound, that there is no legal impediment to CLS’s execution and performance of this Sub-Lease Agreement with MediWound, and that CLS has received the consent of the Principal Lessor for this Sub-Lease Agreement, which consent is attached hereto as Annex C.

 

2.2                               CLS declares that the Main Agreement is in full force and effect, and has not been amended.

 

2.3                               MediWound declares that it is entitled pursuant to any law and agreement to enter into this Sub-Lease Agreement with CLS and that there is no legal impediment to MediWound’s execution and performance of this Sub-Lease Agreement with CLS.

 

2.4                               MediWound declares that it has read the terms and conditions of the Main Agreement and that it has understood said terms and conditions.

 

2.5                               MediWound declares that it has seen and inspected the Main Premises, the Premises, all parts and details thereof and their vicinity, has been advised by CLS to inspect the planning status of the Main Premises and the Premises with the city planning program (“Taba”), and MediWound certifies that it has found the Premises to be suitable for its purposes and objectives from every aspect whatsoever and it renounces any contention of any inconsistency, defect (excluding a “hidden defect”) and any other contention in connection therewith, subject to the validity of CLS’s declarations.

 

2.6                               MediWound declares that it is aware that certain portions of the Main Premises (not including the Premises) are currently sub-leased to third parties, and that CLS may continue to sub-lease these or other portions of the Main Premises (not including the Premises) to any third party.

 

2.7                               CLS declares that in case the office areas specified under Annex D in the first floor of the Main Premises and currently used by MediWound will have to be vacated for any reason, MediWound shall be entitled to receive an additional 90 sq.m. office space on the ground floor.  In this case, an amount of $1,000 (one thousand US dollar) would be added to the current monthly fee (19,000$), and the monthly fee shall be $20,000 (twenty thousand US dollars)

 

2

 

3.                                     The Sub-Lease and MediWound’s undertakings

 

3.1                               Unless specifically set forth otherwise in this Sub-Lease Agreement, MediWound shall be bound by all CLS’s undertakings set forth in the Main Agreement, mutatis mutandis, with respect to the Premises, as if MediWound was CLS in the Main Agreement and CLS were the Principal Lessor in the Main Agreement.  The above shall not include sections 4.1.1.a, 4.1.l.b, 5.1, 5.2, 6.1-6.6, 7.1-7.3, 10.1 and 15 of the Main Agreement.  MediWound undertakes not to carry out any act or omission that may be deemed as a breach by CLS of any provision of the Main Agreement.  CLS covenants that it shall exercise all of its rights pursuant to the Main Agreement towards the Principal Lessor in order to maintain and safeguard MediWound’s rights and interests in the Premises.  MediWound hereby acknowledges that the above shall apply to the Main Agreement, as may be amended from time to time, provided however, that any amendment which has the effect of canceling a right of, or adding additional undertakings to, or having any adverse effect on, MediWound, shall not be binding upon MediWound, unless agreed by MediWound in writing.

 

3.2                               Subject to MediWound upholding all its obligations as set out in this Agreement, CLS hereby leases to MediWound, and, subject to CLS upholding all its obligations as set out in this Agreement, MediWound hereby leases from CLS, the Premises as a sub-lease.  For the avoidance of any doubt, it is agreed that if for any event the Main Agreement is terminated, for any reason whatsoever, this Agreement will be terminated and MediWound will vacate the Premises according to the provisions of this Agreement and shall not have any claim and/or law suit against CLS, unless such termination is as a result of any act or omission by CLS, which constitutes a breach of the Main Agreement or early termination thereof by CLS (not due to a breach of MediWound or the Principal Lessor), in which case CLS shall be liable for all direct losses, damages and expenses incurred by MediWound as a result thereof.

 

3.3                               It is hereby clarified that MediWound or any agents thereof have no rights to use, either on a temporary or permanent basis, any other areas of the Main Premises and/or any contents and furnishing located therein, except the Premises, unless otherwise permitted in this Sub-Lease Agreement or by CLS.

 

3.4                               MediWound hereby undertakes to comply with CLS’s instructions as stipulated in the standard operating procedures and guidelines implemented by CLS in the Main Premises.  CLS will notify MediWound in advance of any such new procedures or guidelines or any changes to existing ones and will give MediWound the opportunity to comment and to discuss the implications thereof with CLS.  In any event, CLS will not unreasonably issue any instructions which may materially disturb MediWound’s business activities in the Premises.  MediWound hereby understands that smoking indoors is forbidden in the entire Main Premises.  MediWound further undertakes to cooperate with the CLS as may be required under the Main Agreement.

 

3.5                               Insurance.  The Monthly Payment (as hereinafter defined) includes the costs of the insurances set forth in Annex F.  CLS will add MediWound to CLS’s “employers’ liability”, “contents” and “manufacturing materials and products” insurance policies, as an additional insured party.  MediWound shall bear any self participation called for according to the insurance policies.  MediWound will undertake to comply with all of the provisions which are specified within the insurance policies and indemnify CLS and hold it harmless if and to the extent CLS suffers damages due to any breach by MediWound of its obligations under the insurance policies.

 

3.6                               Maintenance and Good Repair.  MediWound’s undertakings in accordance with section 11.2 of the Main Agreement, as applied hereto by Section 3.1 shall also apply to CLS’s systems, furniture and equipment in the Premises (as specified in “Annex E”) subject to the provisions hereof.

 

3

 

Notwithstanding section 11.2 of the Main Agreement, MediWound shall immediately notify CLS of any damage or repair required, and may not carry out any repairs without prior coordination with CLS and/or first allowing CLS to perform the repairs, at CLS’s sole discretion.  If CLS fails to carry out the repairs within a reasonable time after notice, MediWound shall be permitted to carry out such repairs, provided it has notified CLS reasonably in advance of doing so.  The cost of repairing damages in the Premises, other than those resulting from normal wear and tear, construction deficiencies or defects in any internal systems installed by or on behalf of CLS (which will be at CLS’s expense), will be at MediWound’s expense.  Each party will reimburse the other for any reasonable costs such other party incurs and which pursuant to the foregoing should be borne by the reimbursing party.  For the avoidance of doubt, none of the above shall impose any obligation on CLS to fix or make any repairs with respect to any equipment which belongs to MediWound.

 

3.7                               Confidentiality.  In exercising any right of CLS pursuant to section 11.3 of the Main Agreement (with respect to entering the Premises), CLS (and the Principal Lessor, only to the extent specifically agreed by it in writing) shall be subject to the confidentiality undertaking set forth in the non-disclosure agreement entered into by CLS and MediWound as specified in Annex F.  For the avoidance of doubt, all the other provisions of section 11 of the Main Agreement shall apply, subject to the provisions of this Agreement.

 

3.8                               Signs.  MediWound shall not erect any sign on the Premises including its external walls and external windows and its vicinity without obtaining the prior written approval of CLS and the Principal Lessor.  MediWound’s name and logo will however be displayed at the entrance to the Main Premises and at such other places as other names and lists of tenants are displayed.

 

3.9                               Improvements and Alterations.  MediWound may not make any improvements, alterations and/or other work on or to the Premises, unless it obtains: (i) CLS’s prior written consent which consent may not be unreasonably withheld; and (ii) the Principal Lessor’s prior written consent, which may be given or withheld in its sole discretion.  Subject to the aforesaid, the other terms of section 7.4 of the Main Agreement, as applied hereto by Section 3.1, shall apply.

 

3.10                        Inspections by Third Parties.  CLS is aware that certain authorities and/or regulatory bodies may request from time to time the inspection of MediWound’s laboratories and clean rooms and CLS hereby warrants that it will duly cooperate with MediWound in order to allow MediWound to fulfill its obligations under applicable local or state laws and regulations.  MediWound shall be entitled to initiate any inspection of the Main Premises by any authority or regulatory body, for any purpose after prior coordination with CLS.

 

3.11                        Regulatory Permits.  CLS and MediWound agree to reasonably cooperate with the representatives and consultants of either party for the purpose of receiving regulatory permits and approvals from bodies in Israel and abroad.  CLS and MediWound agree that they will supply all reasonably necessary documents in order to help with the receipt of these permits and approvals.

 

4

 

4.                                      Effective Date: 1 January, 2004

 

5.                                      Inapplicability of the Tenant Protection Law

 

5.1                               CLS undertakes to lease the Premises to MediWound, and MediWound undertakes to rent the Premises from the CLS, as an unprotected lease, subject to the terms hereof.

 

5.2                               MediWound reiterates its declaration that it has not paid CLS and/or anyone else any “key money” whatsoever or any sum that may be deemed to be “key money”.

 

5.3                               MediWound declares that the provisions of the Tenant Protection Law (Consolidated Version) 5732-1972, or any other similar law to be legislated in the future, including without limitation all amendments thereof and/or regulations and/or orders that have and/or shall be promulgated pursuant thereto, shall not apply to the lease of the Premises and MediWound shall be obligated to vacate the Premises in accordance with the terms of this Agreement, which terms MediWound further acknowledges are known and clear to it.

 

6.                                      Common Area

 

6.1                               MediWound shall be entitled to use in a reasonable manner with other parties, but not exclusively, the cafeteria, meeting rooms, storage areas, toilets, stairs, shelter, corridors and elevator (subject to any applicable limitations referred to in this Agreement), as may reasonably be required to utilize the Premises and enjoy the services pursuant to this Agreement.

 

7.                                      Purpose of the Lease

 

7.1                               MediWound declares and undertakes that it is renting the Premises for use in the nature of biotechnology and pharmaceutical research, development, services and production of clinical trial and commercial material in the field of life-sciences, medical devices and general health care.

 

7.2                               CLS hereby declares that to the best of its knowledge, the purposes set forth in Section 7.1 conform to the uses which are permitted in the current applicable city planning program (“Taba”).

 

8.                                     Term of Lease

 

8.1                               The term of the lease hereunder                     shall commence upon the Effective Date and shall be for a period of twelve (12) months (hereinafter the “Term of Lease”) This Agreement may be automatically renewed for two (2) additional periods of twelve (12) month each, under the same terms and conditions of this Agreement, as long as CLS is the leaser of the main premises, unless either CLS or MediWound decide to terminate this Agreement as defined herein.

 

8.2                               Either party may terminate this Agreement upon a six (6) month prior written notice to the other party.

 

5

 

9.                                      Monthly Fees

 

9.1                               MediWound shall pay the monthly fees, which shall be US$ 19,000 (nineteen thousand US dollars) per month, plus V.A.T., if applicable (the “Monthly Payment”).  The provision of this section 9.1 is a principal and fundamental provision of this Agreement, and the breach thereof constitutes a fundamental breach of the Agreement.

 

9.2                               Either party may decide to suspend or terminate the supply or receipt of the services set forth in Annex G hereof (not including with respect to the size of the Premises), and in Section 9.6 below.  In this case, the terminating party shall give the other party a 60-day prior written notice to that effect, and the Monthly Payment, or the payment set forth under Section 9.6 below, as applicable, shall be adjusted accordingly, from the date that the change enters into effect.

 

9.3                               The Monthly Payment in respect of any portion of a calendar month shall be prorated.  The Monthly Payment shall be paid in NIS according to the representative exchange rate of the USD as set by the Bank of Israel on the date of payment.  The Monthly Payment shall cover the rental fee for the Premises and Services detailed under Annex G.

 

9.4                               The parties agree that additional cost may be added or deducted from this Monthly Payment as detailed in Section 9.2 above and Section 9.6 below.  The parties therefore agree that the actual payment by MediWound to CLS will be calculated in accordance with this Section 9.

 

9.5                               [Reserved]

 

9.6                               Financial and accounting services: MediWound shall provide CLS (or CAC, as shall be elected by CLS) with financial and accounting services to be performed by Ms. Ahuva Frenkel (an independent contractor engaged by MediWound), on a half day basis, per week, for a consideration of US$500 per month, to be paid by CLS to MediWound.  Bookkeeping services: MediWound shall provide CLS (or CAC, as shall be elected by CLS) with bookkeeping services to be performed by Ms. Shirly Dror (an employee of MediWound), on a half day basis, per week, for a consideration of US$500 per month, to be paid by CLS to MediWound.  Either party may decide to suspend or terminate the supply or receipt of the services set forth in this Section, as detailed in Section 9.2 above.

 

The parties hereby confirm that nothing herein shall be construed so as to create a relationship between CLS and any of MediWound’s employees (including, without limitation, with the persons set forth above), of employer-employee, or to create a contractual liability or liability for damages resulting from such a relationship.

 

However, the parties shall bear together, on a pro-rata basis between them, any payments, costs, expenses and liabilities related to the engagement of such persons by MediWound, including without limitation, in the event that any competent court or another judicial authority shall determine that a relationship of employer-employee exists between such person and CLS or MediWound.

 

9.7                              MediWound shall pay the Monthly Payment on a quarterly basis on or prior to the first business day of the following quarter.

 

9.8                               All payments to CLS shall be made by a bank transfer to the bank account in the name of Clal Life Sciences Ltd. (CLS at Bank Hapoalim, Account No. 610610, branch no. 615), or in any other manner, as may be required from time to time by CLS.

 

6

 

10.                               Parking Spaces

 

10.1                        CLS undertakes to provide 13 parking spaces in the building’s parking lot at MediWound’s disposal.  The parking spaces at the MediWound’s disposal shall be such that do not block and are not blocked by other spaces.

 

11.                               Liability and Indemnity

 

Subject to the provisions of Section 3.6 above, MediWound shall be responsible for any loss and/or damage which may be caused to the Main Premises and/or their contents and/or any person and/or corporation including its employees and/or CLS and/or Principal Lessor and/or anyone on their behalf and/or any other third party during the term of the sublease pursuant to this Agreement, which may arise from its use of the Premises, and/or from any other activity of MediWound and all those acting on its behalf.  The above shall not apply to any loss and/or damage (or part or portion thereof) to the extent that it was caused by a breach of this Agreement by CLS or by negligence of CLS, or due to normal wear and tear, construction deficiencies or defects in any internal systems or equipment provided by or on behalf of CLS.  Nothing in the above shall be deemed to derogate from any of the parties’ rights, to seek relief from any third party, including the Principal Lessor.

 

12.                               Transfer and Mortgaging of Rights

 

12.1                        CLS shall be entitled to assign and/or transfer and/or endorse and/or mortgage its rights hereunder in the Premises and/or the Main Premises, in whole or in part, without requiring the MediWound’s consent, provided that the MediWound’s rights hereunder are not prejudiced.

 

12.2                        MediWound undertakes not to transfer and/or endorse and/or to deliver and/or to pledge and/or carry out any transaction, with any of the rights incurred to it hereunder, including not to sub-lease the Premises or any part of it, nor to allow any person or entity to use the Premises, whether for consideration or not, without the prior written consents of (i) CLS, which will not unreasonably withhold its consent; and (ii) the Principal Lessor.

 

13.                               Vacating the Premises

 

Without derogation from MediWound’s undertakings pursuant to Section 3.1 above:

 

13.1                        Upon the termination of the Term of Lease and/or upon any legal termination hereof due to a breach hereof, MediWound undertakes to return the Premises to CLS immediately free and clear of any person and object (excluding furnishing, equipment, fixtures and devices that belong to CLS or the Principal Lessor), and in functional and usable condition, except for reasonable and ordinary wear and tear.  Either party agrees that upon termination of the lease, MediWound is entitled to take all the laboratory equipment in its labs, i.e. equipment that was purchased directly by MediWound, and equipment that was purchased at the time of the establishment of the facilities.  All the equipment that was purchased at the time of the establishment of the facilities, which MediWound is entitled to take is specified in Annex I.

 

13.2                        If MediWound does not fulfill its obligation to fix and/or replace anything in order to vacate the Premises and return it with the aforementioned content therein in the state as required in

 

7

 

Section 16.1, CLS may (but is not obliged), after providing a written notice to MediWound 10 business days in advance, to make every repair and/or replacement at MediWound’s expense.

 

14.                               Termination of the Agreement and breaches

 

14.1                        It is hereby agreed by the parties that Section 16 of the Main Agreement shall apply, mutatis mutandis under this Agreement; provided that the reference in Section 16.2 of the Main Agreement to Sections 5, 6, 8, 10, 13.2, 14 and 15 shall refer to Sections 3, 5, 7, 8, 9, 11, and 12 of this Agreement and that any act or omission by the MediWound that results in a material breach by CLS of the Main Agreement shall also be considered a material breach of this Sub-Lease Agreement.

 

15.                               General Provisions

 

15.1                        No waiver and/or extension shall have any force or effect unless made expressly and in writing; no waiver or extension are to be implied or inferred from any behavior, act or omission of either of the parties.

 

15.2                        CLS, in its capacity as such, hereby agrees to reasonably assist MediWound in obtaining any permits and/or licenses required by law for running the business of MediWound in the Premises.

 

15.3                        Any change hereof of any provisions hereof shall be made in writing.

 

15.4                        MediWound shall only be entitled to set off the sums or rights to which it is entitled from CLS from the sums it owes CLS, with the consent of CLS.

 

15.5                        It is hereby agreed between the parties that the laws of the State of Israel shall govern this Agreement and the jurisdiction with respect to anything connected hereto shall be subject to the exclusive jurisdiction of the competent court in Tel Aviv, Israel.

 

15.6                        Any notice sent by one party to the other party at the addresses appearing in the Preamble hereto shall be deemed to have been received 72 hours from being sent by registered mail.  Notwithstanding the foregoing the address of MediWound during the Term of Lease shall be the Premises.

 

8

 

In Witness Whereof the Parties Have Hereunto Set Their Hand

 

 

	
Clal Life   Sciences L.P.  
    	
MediWound Ltd.
    
	
By its general   partner, Clal Applications Center Ltd.
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
By: 
    	
/s/ Nitza   Kardish  
    	
 
    	
By: 
    	
/s/ Ofer Gonen
    
	
Name: 
    	
Nitza Kardish  
    	
 
    	
Name: 
    	
Ofer Gonen
    
	
Title: 
    	
CEO  
    	
 
    	
Title: 
    	
Director
    
	
Date: 
    	
27/7/04  
    	
 
    	
Date: 
    	
27/07/04
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By: 
    	
/s/Tamar Manor  
    	
 
    	
By: 
    	
/s/Marian   Gorecki
    
	
Name: 
    	
Tamar Manor  
    	
 
    	
Name: 
    	
Marian Gorecki
    
	
Title: 
    	
Director  
    	
 
    	
Title: 
    	
C.E.O.
    
	
Date: 
    	
27/7/04  
    	
 
    	
Date: 
    	
27/7/04
    

 

9

 

Annex A

 

[Annex omitted — original in Hebrew]

 

10

 

Annex B

 

Clal Biotechnology Industries Ltd. (the “Company”) hereby transfers and assigns all its rights and obligations pursuant to a Rental Agreement between the Company and Tamiko Food Industries Ltd. (“Tamiko”) dated November 9th, 2000 (the “Agreement”‘) to Clal Life Sciences L.P. (the “Partnerslrip”).

 

The Partnership shall become a direct party to the Agreement and shall have all the rights and obligations pursuant to the Agreement.

 

The Company shall cease to be a party to the Agreement and shall have no rights or obligations pursuant to the Agreement.

 

The Company shall guarantee to Tamiko the performance of all of the Partnenship’s obligations pursuant to the Agreement.

 

The effective date off this Assignment is November 19, 2002.

 

 

	
Clal Biotechnology   Industries Ltd.
    	
Clal Life Sciences L.P.
    
	
 
    	
 
    
	
By: 
    	
/s/David Haselkorn /   /s/Ophir Shahaf
    	
 
    	
By it general partner,   Clal Application Center Ltd.
    
	
David Maselhorn / Ophir Shahaf
    	
 
    	
/s/David Haselkorn
    
	
 
    	
 
    	
 
    
	
The undersigned hereby agrees to the above assignment:
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Taamiko Food Industries Ltd.
    	
 
    	
 
    
	
By: 
    	
/s/Taamiko Food   Industries Ltd.
    	
 
    	
 
    

 

Guarantee

 

We the undersigned, Clal Biotechnology Industries Ltd, hereby irrevocably and unconditionally undertake and guarantee to Tamiko Food Industries Ltd. the full and punctual performance of all the obligations of Clal Life Sciences L.P. under the Tenancy Agreement dated November 9, 2000 which we transfer and ·assign to the Partnership (hereinafter — the “Agreement’“) and we agree that Tamiko shall be entitled to demand from us the performance of any obligation and any payment under the Agreement which have not been perforrned by the Partnership, without being required to demand the same first from the Partnerslrip and without being required to give us an extension of time. For the avoidance of doubt, it is clarified that we do not waive any right to assert any defense available to the Partnership against Tamiko.

 

11

 

This undertaking and Guarantee applies to all of the Partnership obligations under the Agreement including any condition which will be agreed in the future between the Partnership and Tamiko.

 

 

	
 
    	
/s/David Haselkorn /   /s/Ophir Shahaf
    
	
 
    	
Clal Biotechnology   Industries Ltd.
    
	
 
    	
 
    
	
 
    	
By: David Haselkorn /   Ophir Shahaf
    

 

12

 

Annex C

 

[Annex omitted — original in Hebrew]

 

13

 

Annex D

 

[Annex omitted — Drawing of premises]

 

14

 

Annex E: CLS Equipment and Furniture used by MediWound

 

Telephones:

 

	
Item
    	
 
    	
Number of Units
    	
 
    	
Total
    
	
Panasonic KX-T7433
    	
 
    	
Jean, Amir, Marian,   Lior, Gabi, Andrey, Shirly, Ahuva, Liand, Ronit, Avri
    	
 
    	
11
    
	
Starline
    	
 
    	
Jean 1, Lab 3,   Production 6
    	
 
    	
10
    

 

Furniture:

 

	
Item
    	
 
    	
Place
    	
 
    	
Total
    
	
Secretary station
    	
 
    	
Jean
    	
 
    	
1
    
	
Large office desk
    	
 
    	
Marian, Lior, Shirly,   Ahuva, Linda, Ronit, Avri
    	
 
    	
7
    
	
Small office desk
    	
 
    	
Amir, Gabi, Andrey
    	
 
    	
3
    
	
Table small
    	
 
    	
Kitchen
    	
 
    	
1
    
	
Office chair
    	
 
    	
Jean, Amir, Marian,   Lior, Gabi, Andrey, Mery, Masha, Shirly, Ahuva, Liand, Ronit, Avri
    	
 
    	
13
    
	
Visitor’s chair
    	
 
    	
8 + 2 (Gabi) +2   (Andrey)
    	
 
    	
12
    
	
Computers
    	
 
    	
Shirly, Linda, Ahuva
    	
 
    	
3
    

 

15

 

Annex F:

 

CONFIDENTIALITY AND PROPRIETARY INFORMATION CONTRACT

 

This Contract will confirm the basis under which Clal Life Sciences L.P. Partnership No. 550208375 whose address for the purposes hereof is: 42 Hayarkon Street Yavne 81227, (hereinafter the “CLS”), on the one hand, and

 

MediWound Ltd., a company organized under the laws of the State ofisrael and having its principal place of business at, 42 Hayarkon St. North Industrial Zone Yavne, Israel 81227, Israel (who shall be referred to hereinafter as: “MediWound”), on the other hand,

 

May exchange Proprietary Information (as defined below) relating to both parties’ business activities.

 

The Parties acknowledge that the Proprietary Information is the results of substantial development efforts by the Disclosing Party and its affiliates. Accordingly, each Party agrees that receipt of Proprietary Information from or of the other Party shall be under the following obligations of confidentiality and non-use and the Parties agree as follows:

 

1.                                      As used herein, the term ‘‘Proprietary Information” shall mean all specifications, formulae, know-how, data, test protocols for evaluations, technical descriptions, and business and technical information, patents, patent applications, intellectual property, records, data, results and other pertinent information, which is disclosed in writing or in other tangible form or is disclosed orally, visually or electronically, including through visits in, or usage of, the Premises (as defined in the Unprotected Sub-Lease Agreement, to which this agreement is an Annex) (and including information of third parties occupying the Premises) and identified as confidential under this Contract directly or indirectly by one party or which, under the circumstances surrounding its disclosure ought to be treated as confidential by the disclosing party (the “Disclosing Party”) to the other party (the “Receiving Party”), except that Proprietary Information shall not include information which the Receiving Party can show by written evidence:

 

(a)                                 is, or hereafter becomes, other than through the fault of the Receiving Party, part of the public domain;

 

(b)                                 was in the possession of the Receiving Party prior to disclosure by the disclosing Party, without obligation of confidentiality or restriction on use and was not acquired directly or indirectly from the Disclosing Party,

 

(c)                                  is received by the Receiving Party in good faith without obligation of confidentiality or restriction on use from a third party who is under no contractual or fiduciary obligation with respect thereto;

 

(d)                                 is developed by an employee of the Receiving Party who had no access to Proprietary Information of the Disclosing Party, directly or indirectly, as can be substantiated by written documents.

 

Proprietary Information disclosed under this Contract shall not be deemed to be within the foregoing exceptions merely because such information is embraced by more general information in the public domain or in the Receiving Party’s possession. In addition, any combination of features shall not be deemed to be within the foregoing exceptions merely because individual features are in the public domain or in the Receiving Party’s possession, but only if the combination itself and its principle of operation are in the public domain or in the Receiving Party’s possession.

 

The Proprietary Information will be provided free of charge and will be used only for the purpose of technological evaluation. The Receiving Party agrees that it will treat the Proprietary Information as

 

16

 

the property of the Disclosing Party, will safeguard the Proprietary Information and will prevent third- party access to it.

 

2.                                      The Receiving Party agrees to keep the Disclosing Party’s Proprietary Information in strict confidence and not to disclose the Disclosing Party’s Proprietary Information to any third party (including any affiliates of the Receiving Party), and agrees that the Proprietary Information shall be disclosed only to persons within its organization who need to know the information for the purpose of this Contract and who are bound by written obligations of confidentiality.

 

The Receiving Party shall use no less than the same degree of care in protecting the Disclosing Party’s information than it would use for its own confidential information, but in any event not less than reasonable care and means to prevent the unauthorized use by or the disclosure of the Proprietary Information to third parties. Proprietary Information, including any and all copies or summaries or any dissemination thereof, disclosed under this Contract and all right, title and interest thereto, shall remain the exclusive property of the Disclosing Party. Upon the conclusion of this Contract, or upon request of either Party, each Party shall return to the other party all tangible Proprienuy Information, within its possession or control.

 

3.                                      Nothing contained herein shall be construed as granting one Party a right to use the Proprietary Information in any way or for any purpose other than for the Contract thereof for the purpose mentioned above, or a right or license under any copyright, patent, trade secret, technology or other intellectual property rights of the other Party, nor as obligating one Party to make such grants to the other Party, nor as obligating the Parties to enter into any commercial or other arrangement.

 

4.                                      Receiving Party may not alter, reverse engineer, decompile, disassemble or otherwise modify any Proprietary Information disclosed to Receiving Party.

 

5.                                      No Warranty. ALL PROPRIETARY INFORMATION IS PROVIDED “AS IS”. EACH PARTY MAKES NO WARRANTIES, EXPRESS, IMPLIED OR OTHERWISE, REGARDING ITS ACCURACY, COMPLETENESS OR PERFORMANCE. THE DISCLOSING PARTY SHALL NOT BE LIABLE FOR DAMAGES OF ANY NATURE, INCLUDING CONSEQUENTIAL DAMAGES, AS A RESULT OF OR ARISING OUT OF THE RECEIVING PARTY’S RELIANCE ON OR USE OF THE PROPRIETARY INFORMATION.

 

6.                                      This Contract shall be construed in accordance with, and all disputes hereunder shall be governed by the laws of the State of Israel, without giving effect to the conflicts of laws principals. The parties further agree that any and all controversies, proceedings or disputes in connection with this Contract shall be resolved exclusively in the competent courts of Tel-Aviv, and each of the parties hereby submits irrevocably to the exclusive jurisdiction of such court.

 

7.                                      If any provision of this Contract shall be held by a court of competent jurisdiction to be illegal, invalid or unenforceable, the remaining provisions shall remain in full force and effect.

 

8.                                      This Contract does not create an agency, partnership or joint venture between the Parties.

 

9.                                      All additions or modifications to this Contract must be made in writing and executed by all Parties. The Contract covers the entire understanding between the Parties. None of the provisions of this Contract shall be deemed to have been waived by any act or acquiescence on the part of Disclosing Party, its agents, or employees, but only by an instrument in writing signed by an authorized officer of Disclosing Party. No waiver of any provision of this Contract shall constitute a waiver of any other provision(s) or of the same provision on another occasion.

 

17

 

10.                               The obligations of non-disclosure and non-use shall continue for a period of five (5) years from the termination date of this Contract.

 

18

 

Annex G: The Subleased Area and Related Services

 

1 Laboratories and offices space: the furniture and equipment in Mediwound labs and offices are Mediwound’s property with the exclusion of items specified under Annex E.

 

2 Parking space - thirteen (13) places.

 

3 Taxes: Governmental property taxes, municipal taxes and water.

 

4 Electricity: payment for “public areas”.

 

5 Computer maintenance: maintenance of the various computer servers, network and other related general equipment.

 

6 Cleaning services of the Leased Area and communal areas, on a daily basis.

 

7 General maintenance services of the building and its various systems and fixtures in the Leased Area and the communal areas including but not limited to the various air systems, electricity, water, sewage, communication services (Internet, intranet, phone system, fax lines), and fire alarm and extinguishing systems.

 

8 Security and guarding services.

 

9 Insurance Policies: naming Mediwound as insured, covering the facility for fire, earthquake, terror related damages etc., any third party claims and content including communal areas and fixtures and Mediwound’s property, fixtures and equipment. Section 3.5 further defines Mediwound’s commitments under the insurance policies.

 

10 Meeting rooms- will be available upon prior coordination with CLS.

 

11 Communication - fix price of the communication services, internet services and cellular coordinators.

 

Services incurring additional payment:

 

For the avoidance of doubt, the following expenses will be billed separately by CLS or the appropriate vendor (e.g., mail and delivery), on a monthly basis, and will be borne solely by Mediwound (on a per use basis), in addition to the Monthly Payment:

 

a) Meals per employee, per meal

 

b) Mail and delivery services

 

c) Office expenses

 

d) Electricity- direct use as per the counter located at the main electricity room.

 

e) Telephone& Fax- direct use per line.

 

f) Computer service calls - direct use.

 

g) Refreshments (e.g., coffee, tea, biscuits, etc.)

 

19

 

Annex H: The additional services

 

Financial and accounting services: MediWound shall provide CLS (or CAC, as shall be elected by

 

CLS) with financial and accounting services to be performed by Ms. Abuva Frenkel (an independent contractor engaged by MediWound), on a half day basis, per week, for a consideration of US$500 per month, to be paid by CLS to MediWound. Bookkeeping services: MediWound shall provide CLS (or CAC, as shall be elected by CLS) with bookkeeping services to be performed by Ms. Shirly Dror ([an employee ofMediWound), on a half day basis, per week, for a consideration ofUS$500 per month, to be paid by CLS to MediWound.

 

20

 

Annex I: Lab equipment that was purchase on the establishment of the facilities and belongs to MediWound

 

	
Item
    	
 
    	
manufactor
    
	
 
    	
 
    	
 
    
	
lyophilizer
    	
 
    	
usifroid
    
	
 
    	
 
    	
 
    
	
autoclave fob2s
    	
 
    	
fedegari
    
	
 
    	
 
    	
 
    
	
oven
    	
 
    	
fedegari
    
	
 
    	
 
    	
 
    
	
water system
    	
 
    	
millipore
    
	
 
    	
 
    	
 
    
	
filter press
    	
 
    	
diferbach
    
	
 
    	
 
    	
 
    
	
dish washer
    	
 
    	
laucer
    
	
 
    	
 
    	
 
    
	
chiller
    	
 
    	
unberman
    
	
 
    	
 
    	
 
    
	
stainless steel   versel 250L
    	
 
    	
Egmo
    
	
 
    	
 
    	
 
    
	
stainless steel   verse! 70L
    	
 
    	
Egmo
    
	
 
    	
 
    	
 
    
	
UF
    	
 
    	
filtrone
    
	
 
    	
 
    	
 
    
	
centrassette 5   holder
    	
 
    	
filtrone
    
	
 
    	
 
    	
 
    
	
cassette omega
    	
 
    	
filtrone
    
	
 
    	
 
    	
 
    
	
pump for UF   system
    	
 
    	
fristam
    
	
 
    	
 
    	
 
    
	
trolley for UF   system
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
laminar flow
    	
 
    	
EinDor
    
	
 
    	
 
    	
 
    
	
floor scale
    	
 
    	
prizma
    
	
 
    	
 
    	
 
    
	
chemical hood   (lab)
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Benches
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Diaphragm pump
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Lab cupboard
    	
 
    	
 
    

 

21

 

AMENDMENT TO SUBLEASE AGREEMENT

 

This Amendment to Sub-Lease Agreement (this “Amendment”) is made and entered into this 27 day of November, 2005, by and among MediWound Ltd. (“MediWound”), and Clal Life Sciences L.P. (“CLS”).

 

WHEREAS                              the parties hereto entered into a Sub-Lease Agreement dated as of July 27, 2004, a copy of which is attached hereto as Schedule A (the “Original Agreement”), and;

 

WHEREAS                              MediWound has increased its operations and the consumption of raw materials within the Main Premises and;

 

WHEREAS                              both parties hereto agree to amend and replace certain terms, regarding the Monthly Payment and the Premises, of the Original Agreement according to the terms detailed hereunder.

 

NOW, THEREFORE, it is declared and stipulated between the parties as follows:

 

1.                                      All capitalized terms not herein defined shall have meaning ascribed to them in the Original Agreement.

 

2.                                      The parties hereby agree to add to the Premises leased by MediWound additional office in the first floor (office number 2627B) and additional storage space in the open space of the first floor.  It is hereby agreed that such additional storage space (approximately 50 Square meters) shall be vacated by MediWound, if such space shall be needed by CLS upon two weeks prior written notice to MediWound.

 

3.                                      The parties hereby agree to increase the Monthly Payment made by MediWound to CLS according to Section 9.1 of the Original Agreement to the sum equal to $21,000 (twenty one thousand and five hundred US dollars) per month plus V.A.T., if applicable (the “Monthly Payment”).

 

4.                                      The amendment of the Original Agreement according to this Amendment, shall commence of January 1st, 2006 and continue until the termination of the Original Agreement.

 

5.                                      All other terms and conditions of the Original Agreement shall remain in full force and effect as detailed in the Original Agreement.

 

IN WITNESS WHEREOF, the parties have signed this Amendment as of the date set forth herein.

 

	
Clal Life Sciences   L.P.
   By its general partner, Clal
   Applications Center Ltd
    	
 
    	
MediWound Ltd.
    
	
 
    	
 
    	
 
    
	
/s/ Ofer Gonen /s/ Moti Hacham 
    	
 
    	
/s/ Marian Gorecki  
    
	
Name: Ofer Gonen/Moti Hacham 
    	
 
    	
Name: Marian Gorecki 
    
	
Title: Director/ C.E.O
    	
 
    	
Title: C.E.O
    

 

 

AMENDMENT NO.2 TO UNPROTECTED SUBLEASE AGREEMENT

 

This Amendment to an Unprotected to Sub-Lease Agreement (this “Amendment”) is made and entered into effective as of this 7th day of August 2006, between MediWound Ltd. (“MediWound”), and Clal Life Sciences L.P. (“CLS”).

 

WHEREAS                              a certain Lease Agreement dated as of November 9, 2000 entered by and among Taamiko Food Industries Ltd. and CLS, has been extended until November 1, 2010 (the “Main Agreement”);

 

WHEREAS                              pursuant to Section 13.2 of the Main Agreement, CLS is entitled to enter into a sub-lease agreement;

 

WHEREAS                              the parties hereto entered into a Sub-Lease Agreement dated as of July 27, 2004, as amended by an Amendment to Sub-Lease Agreement dated November 27, 2005 (collectively the “Original Agreement”); and

 

WHEREAS                              both parties hereto agree to amend certain terms, of the Original Agreement as more fully set forth herein.

 

NOW, THEREFORE, it is declared and stipulated between the parties as follows:

 

1.                                      The parties hereby agree to extend the Term of the Lease as defined in Section 8 of the Original Agreement by a period of twelve (12) months until January 1, 2008.  Furthermore, that the Term of Lease of the Original Agreement shall be automatically renewed for two (2) additional periods of twelve months each under the same terms and conditions of the Original Agreement.

 

2.                                      All other terms and conditions of the Original Agreement shall remain in full force and effect.

 

3.                                      This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall together constitute one and the same instrument.

 

IN WITNESS WHEREOF, the parties have signed this Amendment as of the date set forth herein.

 

	
Clal Life Sciences   L.P.
    	
MediWound Ltd.
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/Clal Life Sciences L.P.
    	
/s/MediWound Ltd.
    
	
Name:
    	
Name:
    
	
Title:
    	
Title:
    

 

 

AMENDMENT NO. 3 TO UNPROTECTED SUB LEASE AGREEMENT

 

This Amendment to an Unprotected Sub-Lease Agreement (this “Amendment”) is made and entered into effective as of this 11 day of March, 2008, between MediWound Ltd. (“Mediwound”) and Clal Life Sciences L.P. (“CLS”).

 

WHEREAS,                  a certain Lease Agreement dated as of November 9, 2000 entered by and among Taamiko Food Industries Ltd. and CLS, has been extended until November 1, 2010 (the “Main Agreement”);

 

WHEREAS,                  pursuant to Section 13.2 of the Main Agreement, CLS is entitled to enter into a sub- lease agreement;

 

WHEREAS,                  the parties hereto entered into a Sub-Lease Agreement dated as of July 27, 2004, as amended by an Amendment to Sub-Lease Agreement dated November 27, 2005 and as amended by another Amendment to Sub-Lease Agreement dated August 7, 2006 (collectively the “Original Agreement”); and

 

WHEREAS,                  both parties hereto agree to amend certain terms, of the Original Agreement as more fully set forth herein.

 

NOW, THEREFORE, it is declared and stipulated between the parties as follows:

 

1.                                      All capitalized terms not herein defined shall have the meaning ascribed to them in the Original Agreement.

 

2.                                      The parties hereby agree that Mediwound shall be granted an option commencing from the date of this Agreement to lease the free space of approximately 320 sq/m in the 1st floor of the CLS facility, such option shall expire on 30/6/2008 (the “Option”).  In addition to the Option, CLS shall make its commercially reasonable efforts to offer to Mediwound all available free spaces (the ones that are free today and additional tree spaces that will be vacated in the future) in the CLS facility.

 

3.                                      In return for the Option and as consideration for the Option Mediwound shall pay CLS a one time payment of $8,000 (eight thousand US dollars) by no later than March 31, 2008.

 

4.                                      All other terms and conditions of the Original Agreement, subject to its Amendments, shall remain in full force and effect

 

5.                                      This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall together constitute one and the same instrument.

 

IN WITNESS WHEREOF, the parties have signed this Amendment as of the date set forth herein.

 

	
Clal Life   Sciences L.P.
    	
 
    	
MediWound   Ltd.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/illegible
    	
 
    	
By:
    	
/s/ Gal   Cohen
    
	
(Name & Title)
    	
 
    	
 
    	
Gal   Cohen, Chief Executive Officer
    

 

 

AMENDMENT NO.4 TO UNPROTECTED SUBLEASE AGREEMENT

 

This Amendment to Sub-Lease Agreement (this” Amendment”) is made and entered into this 11 day of Nov., 2008, by and among MediWound Ltd. (“MediWound”), and Clal Life Sciences L.P. (“CLS”).

 

WHEREAS                              the parties hereto entered into a Sub-Lease Agreement dated as of July 27, 2004, as amended by Amendments to Sub-Lease Agreement thereafter (collectively the ‘‘Original Agreement”); copy of which is attached hereto as Schedule A and;

 

WHEREAS                              a certain Lease Agreement dated as of November 9, 2000 entered by and among Taamiko Food Industries Ltd. (the “Principal Lessor”) and CLS, has been extended with a new agreement dated 16/9/2008 attached hereto as Schedule B (both agreement with the Principal Lessor shall be referred to as the “Main Agreement”), and;

 

WHEREAS                              both parties hereto agree to amend and replace certain terms, regarding the Monthly Payment and the Premises, of the Original Agreement according to the terms detailed hereunder.

 

NOW, THEREFORE, it is declared and stipulated between the parties as follows:

 

1.                                      All capitalized terms not herein defined shall have the meaning ascribed to them in the Original Agreement.

 

2.                                      The parties hereby agree to add to the Premises leased by MediWound additional space of approximately 415 sq/m in the first floor on an As Is basis (the “Additional Space”) and to remove and deduct from the Premises other spaces leased and used by MediWound in the first and ground floor, all as specified in the program attached hereto as Schedule C.  Accordingly subject to this Amendment MediWound shall have the right to use the premises it occupied in the ground floor according to the Original Agreement and the additional premises under this Amendment all as detailed in Schedule C attached hereto.

 

3.                                      The parties hereby agree to increase the Monthly Payment made by MediWound to CLS to the sum equal to $ 30,000 (thirty thousand US dollars) per month plus V.A.T., if applicable, (the “Monthly Payment”).

 

4.                                      It is hereby agreed that the Monthly Payment shall be increased by 6% every 2 years from the Date of Commencement hereunder defined.

 

5.                                      This Amendment shall commence on December 15th, 2008 (“Date of Commencement”) and continue until the termination according to the terms of this Amendment.

 

6.                                      MediWound shall vacate any and all offices or any other premises it is currently using and that are not marked as Premises in the attached Schedule C no later than December 25th 2008.

 

7.                                     The term of the Lease shall be for 2 years from the Date of Commencement with an option for 2 additional years.  MediWound shall not be entitled to sublease any portion of the Premises without the prior written approval of CLS and in accordance with the terms and obligations of CLS regarding the Premises.

 

8.                                      Any changes MediWound wishes to carry out within the Premises will have to receive the prior written approval of CLS and will have to be conducted according to the following guidelines:

 

8.1.                            Detailed plans will have to be submitted to CLS, including but not limited to, architecture & electrical planning.

 

 

8.2.                            CLS will determine and approve/decline, subject to CLS’s absolute discretion, and receive any additional approvals for the changes from the Principal Lessor.

 

8.3.                            Following the approval of CLS MediWound shall be responsible to obtain all appropriate approvals from all regulatory, government, municipal (including fire department) or any other relevant entities for the performance of the changes and for the conduct of its business within the Premises as condition precedence for the performance of any changes.

 

8.4.                            MediWound shall be responsible for the work of any contractors; such contractors shall have to work according to detailed guidelines as agreed between MediWound and CLS in order not to excessively disturb the work of other tenants within the CLS facility.

 

9.                                      MediWound shall pay CLS for the consumption of electricity made by MediWound within the Premises or by MediWound’s equipment located and operating outside of the Premises including, but not limited to, air control unites, air conditioning, water system, pumps, WFI system, RO system.

 

10.                               CLS shall reimburse and participate in the costs of improvements made within the Additional Space by MediWound according to the following terms:

 

10.1.                     CLS shall participate in the amount of $100 per sq/meter of improvement for work actually preformed according to the plans pre-approved by CLS according to Section 8 above.

 

10.2.                     Such participation shall be made in 12 equal installments during the first year following the Date of Commencement.

 

11.                               All other terms and conditions of the Original Agreement shall remain in full force and effect as detailed in the Original Agreement.

 

IN WITNESS WHEREOF, the parties have signed this Amendment as of the date set forth herein.

 

 

	
Clal Life Sciences L.P.
    	
 
    	
MediWound Ltd.
    
	
By its general partner, Clal   Applications Center Ltd
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Ofer Gonen /s/ Moti Hacham
    	
 
    	
/s/ Ofer Gonen /s/ Gal Cohen
    
	
Name: Ofer Gonen / Moti Hacham
    	
 
    	
Name: Ofer Gonen / Gal Cohen
    
	
Title: Director / C.E.O 
    	
 
    	
Title: Director / C.E.O
    
	
Date:
    	
 
    	
 
    	
 
    
				

 

 

AMENDMENT NO.5 TO UNPROTECTED SUBLEASE AGREEMENT

 

This Amendment to Sub-Lease Agreement (this “Amendment”) is made and entered into this 29 day of April 2010, by and among MediWound Ltd. (“MediWound”), and Clal Life Sciences L.P. (“CLS”).

 

WHEREAS          the parties hereto entered into a Sub-Lease Agreement dated as of July 27, 2004, as amended by Amendments to Sub-Lease Agreement thereafter (collectively the ‘‘Original Agreement”), copy of which is attached hereto as Schedule A and;

 

WHEREAS          a certain Lease Agreement dated as of November 9, 2000 entered by and among Taamiko Food Industries Ltd. (the “Principal Lessor”) and CLS, has been extended with a new agreement dated 16/9/2008 attached hereto as Schedule B (both agreement with the Principal Lessor shall be referred to as the “Main Agreement”), and;

 

WHEREAS          both parties hereto agree to amend and replace certain terms, regarding the Monthly Payment and the Premises, of the Original Agreement according to the terms detailed hereunder.

 

NOW, THEREFORE, it is declared and stipulated between the parties as follows:

 

1.             All capitalized terms not herein defined shall have the meaning ascribed to them in the Original Agreement.

 

2.             The parties hereby agree to add to the Premises leased by MediWound additional space of approximately 80 sq/m in the ground floor on an As Is basis (the “Additional Space”) all as specified in the program attached hereto as Schedule C.

 

3.             The parties hereby agree to increase the Monthly Payment made by MediWound to CLS to the sum equal to $ 33,350 (thirty three thousand three hundred and fifty US dollars) per month plus V.A.T., if applicable, (the “Monthly Payment”).

 

4.             It is hereby agreed that the Monthly Payment shall be increased by 6% every 2 years from the Date 15, December 2008.

 

5.             This Amendment shall commence on May     th, 2010 (“Date of Commencement”) and continue until the termination according to the terms of this Amendment.

 

6.             The term of the Lease shall be for 2 years from the Date of Commencement with an option for 2 additional years.  MediWound shall not be entitled to sublease any portion of the Premises without the prior written approval of CLS and in accordance with the terms and obligations of CLS regarding the Premises.

 

7.             Any changes MediWound wishes to carry out within the Premises will have to receive the prior written approval of CLS and will have to be conducted according to the following guidelines:

 

7.1.         Detailed plans will have to be submitted to CLS, including but not limited to, architecture & electrical planning.

 

7.2.         CLS will determine and approve/decline, subject to CLS’s absolute discretion, and receive any additional approvals for the changes from the Principal Lessor.

 

7.3.         Following the approval of CLS MediWound shall be responsible to obtain all appropriate approvals from all regulatory, government, municipal (including fire department) or any other relevant entities for the performance of the changes and for the conduct of its

 

 

business within the Premises as condition precedence for the performance of any changes.

 

7.4.         MediWound shall be responsible for the work of any contractors; such contractors shall have to work according to detailed guidelines as agreed between MediWound and CLS in order not to excessively disturb the work of other tenants within the CLS facility.

 

8.             MediWound shall pay CLS for the consumption of electricity made by MediWound within the Premises or by MediWound’s equipment located and operating outside of the Premises including, but not limited to, air control unites, air conditioning, water system, pumps, WFI system, RO system.

 

9.             All other terms and conditions of the Original Agreement shall remain in full force and effect as detailed in the Original Agreement.

 

IN WITNESS WHEREOF, the parties have signed this Amendment as of the date set forth herein.

 

 

	
Clal Life Sciences L.P.  
    	
 
    	
MediWound Ltd.
    
	
By its general partner, Clal   Applications Center Ltd
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Ofer Gonen /s/ Moti Hacham 
    	
 
    	
/s/ Ofer Gonen /s/ Gal Cohen  
    
	
Name: Ofer Gonen / Moti Hacham 
    	
 
    	
Name: Ofer Gonen / Gal Cohen 
    
	
Title:
    	
Director / C.E.O 
    	
 
    	
Title:
    	
Director / C.E.O 
    
	
Date:
    	
29/4/10
    	
 
    	
Date:
    	
29/4/10
    

 

 

AMENDMENT NO. 6 TO UNPROTECTED SUB LEASE AGREEMENT

 

This Amendment to Sub-Lease Agreement (this “Amendment”) is made and entered into this 11 day of 10, 2010, by and among MediWound Ltd. (“MediWound”), and Clal Life Sciences L.P. (“CLS”).

 

WHEREAS          the parties hereto entered into a Sub-Lease Agreement dated as of July 27, 2004, as amended by Amendments to Sub-Lease Agreement thereafter (collectively the “Original Agreement”); copy of which is attached hereto as Schedule A and;

 

WHEREAS          a certain Lease Agreement dated as of November 9, 2000 entered by and among Taamiko Food Industries Ltd. (the “Principal Lessor”) and CLS, has been extended with a new agreement dated 16/9/2008 attached hereto as Schedule B (both agreement with the Principal Lessor shall be referred to as the “Main Agreement”), and;

 

WHEREAS          MediWound wishes to place in the parking area a cooling storage container, and;

 

WHEREAS          both parties hereto agree to amend and replace certain terms of the Original Agreement according to the terms detailed hereunder.

 

NOW, THEREFORE, it is declared and stipulated between the parties as follows:

 

1.             All capitalized terms not herein defined shall have the meaning ascribed to them in the Original Agreement.

 

2.             Subject to the fulfillment of all of the terms detailed hereunder CLS shall not object to placing a cooling storage container in one of MediWound’s parking spaces.

 

3.             Any changes MediWound wishes to carry out within the Premises will have to receive the prior written approval of CLS and will have to be conducted according to the following guidelines:

 

3.1.         Detailed plans will have to be submitted to CLS, including but not limited to, architecture & electrical planning.

 

3.2.         CLS will determine and approve/decline, subject to CLS’s absolute discretion, and receive any additional approvals for the changes from the Principal Lessor.

 

3.3.         Following the approval of CLS MediWound shall be responsible to obtain all appropriate approvals from all regulatory, government, municipal (including fire department) or any other relevant entities for the performance of the changes and for the conduct of its business within the Premises as condition precedence for the performance of any changes.

 

3.4.         MediWound shall be responsible for the work of any contractors and for any and all damages from or arising from such cooling storage container; all contractors shall have to work according to detailed guidelines as agreed between MediWound and CLS in order not to excessively disturb the work of other tenants within the CLS facility.

 

3.5.         MediWound shall be responsible against and to any and all regulatory, governmental, municipal (including fire department) or any other relevant entities for and against any claim resulting from the placement of the cooling storage container in the parking space of MediWound and CLS shall have no such responsibility.

 

3.6.         The space of the parking place that will be used by the cooling storage container will be deducted from the parking spaces designated for MediWound’s use under the original agreement.

 

 

4.             MediWound shall pay CLS for the consumption of electricity made by MediWound within the Premises or by MediWound’s equipment located and operating outside of the Premises including, but not limited to, air control unites, air conditioning, water system, pumps, WFI system, RO system.

 

5.             All other terms and conditions of the Original Agreement shall remain in full force and effect as detailed in the Original Agreement.

 

IN WITNESS WHEREOF, the parties have signed this Amendment as of the date set forth herein.

 

 

	
Clal Life Sciences L.P.  
    	
 
    	
MediWound Ltd.
    
	
By its general partner, Clal   Applications Center Ltd  
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Ofer Gonen /s/Moti Hacham 
    	
 
    	
/s/ Ofer Gonen /s/Gal Cohen  
    
	
Name: Ofer Gonen / Moti Hacham 
    	
 
    	
Name: Ofer Gonen / Gal Coben 
    
	
Title:
    	
Director /   C.E.O 
    	
 
    	
Title:
    	
Director / C.E.O 
    
	
Date:
    	
12/10/10
    	
 
    	
Date: 
    	
11/10/10
    

 

 

AMENDMENT NO. 7 TO UNPROTECTED SUB LEASE AGREEMENT

 

This Amendment to Sub-Lease Agreement (this “Amendment”) is made and entered into this 18th day of December, 2013, by and among MediWound Ltd. (“MediWound”), and Clal Life Sciences L.P. (“CLS”).

 

WHEREAS          the parties hereto entered into a Sub-Lease Agreement dated as of July 27, 2004, as amended by Amendments to Sub-Lease Agreement thereafter (collectively the “Original Agreement”); copy of which is attached hereto as Schedule A and;

 

WHEREAS          a certain Lease Agreement dated as of November 9, 2000 entered by and among Taamiko Food Industries Ltd. (the “Principal Lessor”) and CLS, has been extended with a new agreement dated 161912008 attached hereto as Schedule B (both agreement with the Principal Lessor shall be referred to as the “Main Agreement”), and;

 

WHEREAS          both parties hereto agree to amend and replace certain terms, regarding the extension of the term and Monthly Payment and the Premises, of the Original Agreement according to the terms detailed hereunder.

 

NOW, THEREFORE, it is declared and stipulated between the parties as follows:

 

1.     All capitalized terms not herein defined shall have the meaning ascribed to them in the Original Agreement.

 

2.     This Amendment shall commence on January 1st 2014 (“Date of Commencement”) and continue until the termination according to the terms of this Amendment.

 

3.     The term of the Lease shall be extended for 2 years from the Date of Commencement with an option to MediWound to extend the lease for 2 additional terms of 1 year each under the same terms. MediWound shall not be entitled to sublease any portion of the Premises without the prior written approval of CLS and in accordance with the terms and obligations of CLS regarding the Premises.

 

It is herby agreed that the Monthly Payment shall be increased by 6% every 2 years from the Date of Commencement (i.e., the next 6% increase will take place on January 1, 2016 and will valid until December 31, 2017). Current Monthly Payment on the Date of Commencement is $38,600 (thirty eight thousand six hundred US Dollars).

 

4.     All other terms and conditions of the Original Agreement shall remain in full force and effect as detailed in the Original Agreement.

 

IN WITNESS WHEREOF, the parties have signed this Amendment as of the date set forth herein.

 

	
Clal Life Sciences L.P.
    	
 
    	
MediWound Ltd.
    
	
By its general partner, Clal Applications   Center Ltd.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/Gil Milner / /s/Moti Hacham
    	
 
    	
/s/Ofer Gonen / /s/Gal Cohen
    
	
Name: Gil Milner / Moti Hacham
    	
 
    	
Name: Ofer Gonen / Gal Cohen
    
	
Title:
    	
Director /   C.E.O
    	
 
    	
Title:
    	
Director / C.E.O.
    
	
Date:
    	
12/18/13
    	
 
    	
Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]